TBI-1501
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase I/IIActive
Key Facts
Indication
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase
Phase I/II
Status
Active
Company
About Takara Bio
Takara Bio's mission is to contribute to the advancement of life sciences and the improvement of human health through its integrated technology platforms. The company has achieved global leadership in PCR reagents, established a top-tier viral vector CDMO, and is advancing a pipeline of in-house gene and cell therapies. Its strategy hinges on the synergistic interplay between its Bioindustry, Gene Therapy, and Cell Medicine segments, creating a unique, full-spectrum biotech enterprise that monetizes innovation from the lab bench to the clinic.
View full company profileTherapeutic Areas
Other Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) Drugs
| Drug | Company | Phase |
|---|---|---|
| Obecabtagene autoleucel (obe-cel) | Autolus Therapeutics | Phase 2 / Pivotal |